NCT00596297

Preoperative Bevacizumab for Vitreous Hemorrhage

Intra-Operative and Postoperative Intraocular Bleeding After Pars Plana Vitrectomy for Vitreous Hemorrhage in Diabetic Patients Previously Treated With Intravitreal Bevacizumab

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous hemorrhage.

Conditions

• Diabetic Retinopathy
• Vitreous Hemorrhage

Interventions

Type	Name	Description
DRUG	bevacizumab	Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
PROCEDURE	pars plana vitrectomy	4 weeks after baseline

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2008-01-16
• Last updated: 2008-10-03

Locations

1 site across 1 country: Brazil